ResearcherNippon Medical SchoolNo recent work listed

Hiroki Sumiyoshi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5028434308. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2016: 1 paper

Papers 1

Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Co-author DOI 10.3892/or.2016.4727 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Eiji Uchida · 1 shared paper, 2016 · strength 0.07
- Paper Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. DOI 10.3892/or.2016.4727 ↗
Yoko Matsuda · 1 shared paper, 2016 · strength 0.07
- Paper Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. DOI 10.3892/or.2016.4727 ↗
Akira Matsushita · 1 shared paper, 2016 · strength 0.07
- Paper Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. DOI 10.3892/or.2016.4727 ↗
Zenya Naito · 1 shared paper, 2016 · strength 0.07
- Paper Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. DOI 10.3892/or.2016.4727 ↗
Toshiyuki Ishiwata · 1 shared paper, 2016 · strength 0.07
- Paper Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. DOI 10.3892/or.2016.4727 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.